England’s High Court has ruled it is lawful to use Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD) instead of more expensive approved drugs ...

Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...

The UK drugs regulator has endorsed the use of Roche’s Avastin as a treatment for age-related macular degeneration, a leading cause of blindness, even though it isn’t approved for that use.

marketed as Tecentriq and Avastin by Roche (OTCQX:RHHBY) (OTCQX:RHHBF). The global Phase 1b/2 study tested amezalpat in combination with atezolizumab and bevacizumab against the standard of care ...

Twelve NHS bodies in the north east of England were offering these patients Avastin, a cheaper alternative to the licensed drug, Lucentis. David Hambleton, chief executive officer of NHS South ...

The Mumbai-based chemical generics manufacturer is taking aim at top-selling biologics—Roche's Avastin (bevacizumab) and Herceptin (trastuzumab) and Pfizer/Amgen's Enbrel (etanercept)—which ...